{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.4","value":"1.2"},{"groupId":"OG001","spread":"0.6","value":"0.36"},{"comment":"Mean percentage of CD3+/CSFSE-low/IFN-gamma+ cells was zero, therefore no standard of deviation","groupId":"OG002","spread":"NA","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Complete Response (CR) patients at Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.6","value":"7.3"},{"groupId":"OG001","spread":"3","value":"13.3"},{"groupId":"OG002","spread":"2.1","value":"4.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"CR patients at Cycle 3 Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.4","value":"6.3"},{"groupId":"OG001","spread":"5.1","value":"13.7"},{"groupId":"OG002","spread":"1.4","value":"3.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"CR patients at end of Study"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.44","value":"0.43"},{"groupId":"OG001","spread":"0.7","value":"0.45"},{"comment":"Mean percentage of CD3+/CSFSE-low/IFN-gamma+ cells was zero, therefore no standard of deviation","groupId":"OG002","spread":"NA","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Progressive Disease (PD) patients at Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"1.7"},{"groupId":"OG001","spread":"1.4","value":"5.7"},{"comment":"Mean percentage of CD3+/CSFSE-low/IFN-gamma+ cells was zero, therefore no standard of deviation","groupId":"OG002","spread":"NA","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"PD patients at Cycle 3 Day 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0.4"},{"groupId":"OG001","spread":"0","value":"0.21"},{"groupId":"OG002","spread":"0","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"PD patients at end of study"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"Immunity is measured by the percentage of CD3+/CSFSE-low/IFN-gamma+ cells. A positive result for a given participant is defined as greater than two standard deviations above that participant's baseline. The data are presented as three groups because the responses were analyzed separately, but all participants were part of the single study arm as represented by the remainder of the record. GVAX-specific immune response and Prevnar-specific immune response was assessed in the same patient by using GVAX and Prevnar-specific co-markers.","dispersionType":"Standard Deviation","groups":[{"description":"Lenalidomide: Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).","id":"OG000","title":"Pre-vaccine (Baseline)"},{"description":"Allogeneic Myeloma Vaccine: A total of 4 doses will be administered. The first three at monthly intervals and a booster at 6 months from the initial dose. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.","id":"OG001","title":"GVAX Vaccine"},{"description":"Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.","id":"OG002","title":"Prevnar Vaccine"}],"paramType":"MEAN","populationDescription":"Out of the 16 baseline participants, one received only one dose of vaccine and then had progression of disease. He was replaced and not included in this analysis. Only 8/15 participants experienced complete response (CR), therefore only 8 participants analyzed in the CR rows and 7 participants analyzed in the progressive disease (PD) rows.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 3 Day 14, end of study (up to 1 year)","title":"Tumor-specific Immunity as Assessed by Percentage of CD3+/CSFSE-low/IFN-gamma+ Cells","type":"SECONDARY","unitOfMeasure":"percentage of cells"}